Shannon M. Campbell, DO, Ohio University College of Osteopathic Medicine, Department of Specialty Medicine, O’Bleness Memorial Hospital, Athens, Ohio; Sara B. Peters, MD, The Ohio State University, Division of Dermatopathology, Columbus, Ohio; Matthew J. Zirwas, MD, The Ohio State University, Division of Dermatology, Columbus, Ohio; Henry K. Wong, MD, The Ohio State University, Division of Dermatology, Columbus, Ohio

Disclosure: Drs. Campbell, Peters, and Zirwas have no conflict of interests to declare. Dr. Wong has served as an advisor for EISAI.

Abstract
The application of CD markers to medicine has advanced our understanding of several dermatological diseases, most notably primary cutaneous lymphomas. CD markers are monoclonal antibodies that target cell surface molecules on leukocytes and antigens from other cells. T-cell processes are typically CD3+, CD20-, CD45+ while B-cell processes are typically CD3-, CD20+, and CD45+. Other CD markers are used to further delineate cutaneous lymphomas. Although an imperfect system, CD markers empower dermatologists to synthesize immunophenotyping with clinical findings and formulate an appropriate diagnosis.  (J Clin Aesthet Dermatol. 2010;3(10):21–25.) Read the rest of this article »

James Q. Del Rosso, DO, Dermatology Residency Director, Valley Hospital Medical Center, Las Vegas, Nevada; Radhakrishnan Pillai, PhD, Associate Director Project Management, Dow Pharmaceutical Sciences Inc., Petaluma, California; Robert Moore, PhD, Associate Principal Scientist, Dow Pharmaceutical Sciences Inc., Petaluma, California

Disclosure: Dr. Del Rosso is a consultant, speaker, and researcher for Coria/Valeant, Allergan, Galderma, Graceway, Intendis, Medicis, Onset Therapeutics, Ortho Dermatologics, Pharmaderm/Nycomed, Promius, Ranbaxy, Stiefel/GSK, Triax, Unilever, and Warner-Chilcott. Drs. Pillai and Moore are employees of Dow Pharmaceutical Sciences Inc. Read the rest of this article »

Sharon E. Jacob, MD, Univeristy of Miami, Department of Dermatology and Cutaneous Surgery, Miami, Florida, University of California, San Diego, Division of Dermatology,
San Diego, California; Aparche Yang, MD, University of California–Los Angeles, Department of Pathology and Laboratory Medicine Division of Dermatopathology; Elise Herro, MD, University of California, San Diego, Division of Dermatology, San Diego, California; Chi Zhang, PhD, University of Miami, Director of Program Evaluation, Miami, Florida; Consultant (research methodology and statistical analyses)

Disclosure: The authors report no relevant conflicts of interest. Dr. Jacob has served as an investigator for Smarthealth USA on the PREA trial investigating the efficacy and safety of the TRUE test in children. Read the rest of this article »

Jenny L. Nelson, MD; Christen M. Mowad, MD
Department of Dermatology, Geisinger Medical Center, Danville, Pennsylvania

Disclosure: The authors report no relevant conflicts of interest. Read the rest of this article »

Amylynne J. Frankel, MD, Mount Sinai Medical Center, New York, New York; Joshua A. Zeichner, MD, Assistant Professor of Dermatology, Mount Sinai Medical Center, New York, New York; James Q. Del Rosso, DO, FAOCD, Dermatology Residency Director, Valley Hospital Medical Center, Las Vegas, Nevada

Disclosure: Dr. Frankel reports no relevant conflicts of interest. Dr. Zeichner is a consultant for Promius. Dr. Del Rosso is a consultant, speaker, and or researcher for Allergan, Coria, Galderma, Graceway, Intendis, Leo Pharma, Medicis, Onset Therapeutics, Ortho Dermatology, PharmaDerm, Promius, Quinnova, Ranbaxy, SkinMedica, Stiefel, Triax, Unilever, and Warner Chilcott. Read the rest of this article »

Stephanie J. Martin, BA, Medical School, The University of Texas Medical School at Houston, Houston, Texas; Philip R. Cohen, MD, Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas, Department of Dermatology, University of Texas Medical School at Houston, Houston, Texas, University of Houston Health Center, University of Houston, Houston, Texas; Jeong Hee Cho-Vega, MD, PhD, St. Joseph Dermpath, Houston, Texas; Jaime A. Tschen, MD, Medical School, The University of Texas Medical School at Houston, Houston, Texas, St. Joseph Dermpath, Houston, Texas.

Disclosure: The authors report no relevant conflicts of interest. Read the rest of this article »

Howard Bargman, MD, FRCPC

Dr. Bargman is Certified Medical Laser Safety Officer, Director of Laser, Sunnybrook Health Sciences Centre, Toronto, Canada.

This installment of Laser Safety focuses on the laser classification system. The nomenclature has changed recently and some issues are somewhat confusing. Therefore, I will try to simplify the classification system and highlight what is important. Read the rest of this article »